Mid-Atlantic BioTherapeutics, Inc. Launches $5 Million Regulation D 506(c) Funding Round to Support Clinical Program Acceleration and Expand the Company’s Global Reach and Market Presence
Mid-AtlanticBioTherapeutics, Inc. (the “Company”), a clinical-stage biotechnology company specializing in cutting-edge immunotherapies and central nervous system (“CNS”)disorder treatments, today announced the commencement of afundraising round under Regulation D, Rule 506(c) of the Securities Act of 1933, as amended (the “Securities Act”). The Company is offering up to $5 million in common stock on a best-efforts […]